Trial Profile
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Guadecitabine (Primary) ; Rasdegafusp-alfa (Primary) ; Poly ICLC
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2025.
- 02 Apr 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2025.
- 01 Apr 2023 Planned End Date changed from 31 Mar 2023 to 31 Mar 2024.